~~<i id='D18374F398'><strike id='D18374F398'><tt id='D18374F398'><pre id='D18374F398'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：leisure time 2025-09-29 23:29:06 Page View：8

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： With competition flaring, obesity drug hits goal in liver disease study
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

explore

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

6 surprising facts about sugar

RaulArboleda/AFP/GettyImagesThesamehormonethatcontrolsorgasmsalsocontrolstheproductionofbreastmilk.

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

Mirador, a new biotech startup, launches with $400 million

AdobeWhathappensafteryoucloseanearly$11billionacquisition?Well,forPrometheusTherapeutics’formerCEOMa